Medicxi, a European life sciences venture capital firm, has closed Medicxi V, a €500m fund dedicated to building and backing biotechnology companies. The oversubscribed fund closed with support from existing limited partners and a select group of new institutional investors. The fund will focus on Medicxi’s asset-centric investment model.
Medicxi has created 16 new companies, delivered over 20 positive clinical data readouts and has realised over $1bn across its portfolio since its last fundraise, including from investments in Vaxcyte, Merus and Abivax, and the acquisitions of ViceBio (Sanofi), Versanis Bio (Eli Lilly) and ProfoundBio (Genmab).
Medicxi V will continue the firm’s focus on supporting drug developers and entrepreneurs in creating asset-focused biotechnology companies to deliver therapies for patients. The investing partners in Fund V are Francesco De Rubertis, Giovanni Mariggi, Nick Williams and Shyam Masrani.
